Literature DB >> 8132323

Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo.

K Takada1, N Ohno, T Yadomae.   

Abstract

Endotoxin (lipopolysaccharide [LPS]) released during gram-negative bacterial infection induces varieties of cytokines which directly and/or indirectly cause shock, disseminated intravascular coagulation, and death. We previously showed that lysozyme (LZM) was an LPS-binding protein and inhibited various immunomodulating activities of LPS. In this study, we examined the effect of LZM on the LPS-triggered septic shock model induced by carrageenan treatment and assessed by tumor necrosis factor production. The data presented in this report strongly suggest that LZM-LPS complex formation completely abrogates tumor necrosis factor production and the mortality caused by LPS and that LZM may be useful for the treatment of endotoxin shock.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132323      PMCID: PMC186250          DOI: 10.1128/iai.62.4.1171-1175.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

2.  Primary structure of limulus anticoagulant anti-lipopolysaccharide factor.

Authors:  J Aketagawa; T Miyata; S Ohtsubo; T Nakamura; T Morita; H Hayashida; T Miyata; S Iwanaga; T Takao; Y Shimonishi
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

Review 3.  Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.

Authors:  H A Ball; J A Cook; W C Wise; P V Halushka
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

4.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

Authors:  I C Kettelhut; W Fiers; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

6.  Biochemical factors in pulmonary inflammatory disease.

Authors:  I Schraufstatter; S D Revak; C G Cochrane
Journal:  Fed Proc       Date:  1984-10

7.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

8.  A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein.

Authors:  C E Ooi; J Weiss; P Elsbach; B Frangione; B Mannion
Journal:  J Biol Chem       Date:  1987-11-05       Impact factor: 5.157

9.  Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum.

Authors:  P S Tobias; K Soldau; R J Ulevitch
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

10.  Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice.

Authors:  V Lehmann; M A Freudenberg; C Galanos
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  15 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Identification of lipopolysaccharide-binding proteins in porcine milk.

Authors:  Farshid Shahriar; John R Gordon; Elemir Simko
Journal:  Can J Vet Res       Date:  2006-10       Impact factor: 1.310

4.  Anti-Inflammatory Effects of Lysozyme Against HMGB1 in Human Endothelial Cells and in Mice.

Authors:  Wonhwa Lee; Sae-Kwang Ku; Dong Hee Na; Jong-Sup Bae
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

Review 5.  Production of human lactoferrin and lysozyme in the milk of transgenic dairy animals: past, present, and future.

Authors:  Caitlin A Cooper; Elizabeth A Maga; James D Murray
Journal:  Transgenic Res       Date:  2015-06-10       Impact factor: 2.788

6.  An in vitro investigation of immunomodulatory properties of Lactobacillus plantarum and L. delbrueckii cells and their extracellular polysaccharides.

Authors:  Mana Kishimoto; Ryohei Nomoto; Masashi Mizuno; Ro Osawa
Journal:  Biosci Microbiota Food Health       Date:  2017-03-22

7.  Consumption of pasteurized human lysozyme transgenic goats' milk alters serum metabolite profile in young pigs.

Authors:  Dottie R Brundige; Elizabeth A Maga; Kirk C Klasing; James D Murray
Journal:  Transgenic Res       Date:  2009-10-22       Impact factor: 2.788

8.  The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides.

Authors:  G Martínez de Tejada; J Pizarro-Cerdá; E Moreno; I Moriyón
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  Oral Treatment with Extract of Agaricus blazei Murill Enhanced Th1 Response through Intestinal Epithelial Cells and Suppressed OVA-Sensitized Allergy in Mice.

Authors:  Go Bouike; Yosuke Nishitani; Hideyuki Shiomi; Masaru Yoshida; Takeshi Azuma; Takashi Hashimoto; Kazuki Kanazawa; Masashi Mizuno
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-26       Impact factor: 2.629

10.  Lysozyme transgenic goats' milk positively impacts intestinal cytokine expression and morphology.

Authors:  Caitlin A Cooper; Dottie R Brundige; Wade A Reh; Elizabeth A Maga; James D Murray
Journal:  Transgenic Res       Date:  2011-02-11       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.